Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Eric E. Bouhassira, PhD
Researcher Professor, Department of Medicine (Hematology)
Albert Einstein College of Medicine
1300 Morris Park Avenue
Ullmann Building, Room 903A
Bronx, New York, United States
Dr. Eric E. Bouhassira joined the Albert Einstein College of Medicine in 1990. He began studying human embryonic stem cells in 2001. He is Director of the Medical School’s Center for Human Embryonic Stem Cell Research and Professor of Medicine and of Cell Biology. Dr. Bouhassira’s research focuses on developing hematopoietic (blood forming) stem cells that can differentiate into red blood cells, T cells, platelets, and all other cell types that comprise blood. This work could potentially aid patients needing transfusions and also save lives by expanding the immunology diversity of hematopoietic stem cells available for transplant.
Dr. Bouhassira is also interested in epigenetic regulation in the erythoid and hematopoietic lineage with a focus on DNA replication and DNA methylation. Dr. Bouhassira received his BS, MS, and PhD degrees from the Université Pierre et Marie Curie in Paris, France. Dr. Bouhassira also holds the Ingeborg and Ira Rennert Chair in Stem Cell Biology and Regenerative Medicine.
Areas of Research:
Pluripotent stem cells, erythroid differentiation, red blood cells, epigenetics, DNA methylation, DNA replication, bioinformatics, allele-specific expression, gene therapy, hemoglobinopathies
Related Content
-
Jon Mark Hirshon, MDJon Mark Hirshon, MD, PhD, MPH, FACEP, F...
-
Teens with Sickle Cell Disease Moving from Pediatric Care to Adult CareMoving from pediatric (children’s) car...
-
Jeff Glassberg, MDDr. Jeffrey Glassberg obtained his MD an...
-
University of Illinois HospitalThe Sickle Cell Program at UI Health is ...
-
4 Transition Stages of Sickle Cell Disease and Tips for Each Stagehttps://www.onescdvoice.com/wp-content/u...
-
University of Pittsburgh Medical CenterPeople with inherited blood disorders re...
-
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...